Vaishali Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Vaishali Pharma has a total shareholder equity of ₹677.6M and total debt of ₹123.5M, which brings its debt-to-equity ratio to 18.2%. Its total assets and total liabilities are ₹1.0B and ₹361.9M respectively. Vaishali Pharma's EBIT is ₹9.6M making its interest coverage ratio 1.3. It has cash and short-term investments of ₹11.4M.
Key information
18.2%
Debt to equity ratio
₹123.46m
Debt
| Interest coverage ratio | 1.3x |
| Cash | ₹11.43m |
| Equity | ₹677.63m |
| Total liabilities | ₹361.85m |
| Total assets | ₹1.04b |
Recent financial health updates
Is Vaishali Pharma (NSE:VAISHALI) A Risky Investment?
Dec 11
Vaishali Pharma (NSE:VAISHALI) Seems To Use Debt Quite Sensibly
Dec 10These 4 Measures Indicate That Vaishali Pharma (NSE:VAISHALI) Is Using Debt Reasonably Well
Feb 10Does Vaishali Pharma (NSE:VAISHALI) Have A Healthy Balance Sheet?
Jan 19
Recent updates
Market Cool On Vaishali Pharma Limited's (NSE:VAISHALI) Revenues Pushing Shares 26% Lower
Jan 17Investors Give Vaishali Pharma Limited (NSE:VAISHALI) Shares A 33% Hiding
Nov 15A Piece Of The Puzzle Missing From Vaishali Pharma Limited's (NSE:VAISHALI) 27% Share Price Climb
Sep 13The Market Lifts Vaishali Pharma Limited (NSE:VAISHALI) Shares 26% But It Can Do More
Jul 05Here's Why Vaishali Pharma (NSE:VAISHALI) Has Caught The Eye Of Investors
Jan 17Vaishali Pharma Limited's (NSE:VAISHALI) Shares Leap 30% Yet They're Still Not Telling The Full Story
Dec 18Is Vaishali Pharma (NSE:VAISHALI) A Risky Investment?
Dec 11We Ran A Stock Scan For Earnings Growth And Vaishali Pharma (NSE:VAISHALI) Passed With Ease
Oct 04With EPS Growth And More, Vaishali Pharma (NSE:VAISHALI) Makes An Interesting Case
Feb 04Vaishali Pharma (NSE:VAISHALI) Seems To Use Debt Quite Sensibly
Dec 10We Ran A Stock Scan For Earnings Growth And Vaishali Pharma (NSE:VAISHALI) Passed With Ease
Aug 20Should You Be Adding Vaishali Pharma (NSE:VAISHALI) To Your Watchlist Today?
May 19These 4 Measures Indicate That Vaishali Pharma (NSE:VAISHALI) Is Using Debt Reasonably Well
Feb 10A Look At The Intrinsic Value Of Vaishali Pharma Limited (NSE:VAISHALI)
Aug 17A Look At The Fair Value Of Vaishali Pharma Limited (NSE:VAISHALI)
May 17Are Vaishali Pharma Limited's (NSE:VAISHALI) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Mar 17Calculating The Fair Value Of Vaishali Pharma Limited (NSE:VAISHALI)
Feb 15Does Vaishali Pharma (NSE:VAISHALI) Have A Healthy Balance Sheet?
Jan 19Are Vaishali Pharma Limited's (NSE:VAISHALI) Mixed Financials Driving The Negative Sentiment?
Nov 23Financial Position Analysis
Short Term Liabilities: VAISHALI's short term assets (₹983.9M) exceed its short term liabilities (₹329.7M).
Long Term Liabilities: VAISHALI's short term assets (₹983.9M) exceed its long term liabilities (₹32.2M).
Debt to Equity History and Analysis
Debt Level: VAISHALI's net debt to equity ratio (16.5%) is considered satisfactory.
Reducing Debt: VAISHALI's debt to equity ratio has reduced from 71.9% to 18.2% over the past 5 years.
Debt Coverage: VAISHALI's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: VAISHALI's interest payments on its debt are not well covered by EBIT (1.3x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 13:30 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vaishali Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|